SELENOP and neuroblastoma: Their findings demonstrated that inhibiting the SELENOP/LRP8 axis represents a novel and selective strategy to trigger ferroptosis, thereby limiting the growth of highly aggressive and treatment-resistant MYCN-amplified neuroblastoma cells, confirming LRP8 as a promising therapeutic target [22].